Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each. Hims & Hers Health ( NYSE:HIMS) received two separate upgrades after resolving its legal dispute with Novo Nordisk (NYSE:NVO) through a distribution partnership. Teladoc Health ( NYSE:TDOC) earned a Buy from Deutsche Bank on valuation and a clearer strategic path for its struggling BetterHelp segment. And Alector ( NASDAQ:ALEC) was lifted to Buy by BTIG as its blood-brain barrier platform repositions the company following a frontotemporal dementia trial setback. Across all three, analysts are pointing to reduced uncertainty rather than accelerating fundamentals as the core thesis.

Ticker Company Firm Old Rating New Rating New Price Target One-Line Takeaway HIMS Hims & Hers Health BofA Underperform Neutral $23 Lawsuit cleared, but Street sees balanced risk/reward at current levels HIMS Hims & Hers Health Deutsche Bank Hold Hold $28 Legal overhang removed; strategic shift away from compounded semaglutide noted TDOC Teladoc Health Deutsche Bank Hold Buy $11 Compelling valuation with credible BetterHelp turnaround path ALEC Alector BTIG Neutral Buy $6 ABC platform pivot removes post-trial uncertainty; neurodegeneration upside intact The Analyst’s Case Hims & Hers Health (HIMS)

BofA upgraded HIMS from Underperform to Neutral, raising its price target from $12.50 to $23. The firm cited the dismissal of Novo Nordisk’s lawsuit as a clear positive, removing a significant legal cloud that had weighed on the stock. BofA is staying below Street consensus on 2026-2027 revenue estimates, signaling the upgrade reflects reduced downside rather than a conviction call on growth. Deutsche Bank kept its Hold rating but raised its target to $28, pointing to the strategic significance of the pivot away from compounded semaglutide and the removal of legal overhang. Both firms characterize the current risk/reward as balanced.

Teladoc Health (TDOC)

Deutsche Bank upgraded Teladoc from Hold to Buy with a $11 price target, a meaningful premium to its current price. The firm’s thesis rests on three pillars: compelling valuation at current levels, a credible longer-term growth plan for the BetterHelp mental health segment, and an illustrated exit path for that business supported by comparable transaction data. The Integrated Care segment, which grew 2% in Q3 2025, continues to provide a stable revenue base while management works to stabilize BetterHelp.

Alector (ALEC)

BTIG upgraded Alector from Neutral to Buy with a $6 price target. The upgrade reflects confidence in the company’s strategic pivot toward its Alector Brain Carrier (ABC) platform following the Phase 3 failure of latozinemab in frontotemporal dementia. BTIG argues that Alector’s combined expertise in protein engineering and disease mechanisms, now fully directed toward novel BBB-shuttle-enabled therapeutics, positions it as a potential significant player in neurodegeneration. The GSK collaboration on nivisnebart (AL101) in Alzheimer’s disease provides a near-term catalyst and de-risks late-stage development costs.

Company Snapshot & Recent Performance

HIMS has had a volatile 2026 following an equally volatile 2025. The stock entered the year at $32.47 and fell sharply on FDA and legal pressure related to compounded semaglutide, but surged 34.47% over the past week through March 9 following the Novo Nordisk partnership announcement. The stock currently trades at $22.16, still down 31.75% year to date. Underlying fundamentals remain strong: FY2025 revenue reached $2.35B, up 59% year over year, with 2.5M+ subscribers and 2026 revenue guidance of $2.70B to $2.90B.

Teladoc trades at $5.30, down 24.29% year to date and 42.08% over the past year. The company reported Q3 2025 revenue of $626.44M, missing the $638.43M consensus estimate, with BetterHelp revenue declining 8% to $236.9M. Full-year 2025 guidance called for revenue of $2.51B to $2.54B.

Alector trades at $2.19, up 40.38% year to date as investors have begun pricing in the ABC platform pivot. The company holds $256M in cash, expected to fund operations through 2027, and beat Q4 2025 revenue estimates significantly, reporting $6.24M against a $2.11M consensus.

Why the Move Matters Now

For HIMS, the Novo Nordisk partnership is more than a legal resolution. It signals a potential path to becoming a branded GLP-1 distributor, which would reduce the company’s dependence on compounded semaglutide and the regulatory risk that comes with it. The stock’s 34.47% one-week surge reflects how much of that overhang had been priced in. BofA’s new $23 target sits close to current trading levels, while Deutsche Bank’s $28 target implies more room to run if the Novo relationship matures.

For Teladoc, Deutsche Bank’s $11 Buy target against a $5.30 current price represents substantial implied upside and reflects the firm’s view that the market is underpricing the value of the Integrated Care segment and a potential BetterHelp transaction or restructuring. Deutsche Bank’s thesis centers on valuation and a longer-term turnaround timeline for the BetterHelp segment.

For Alector, the BTIG upgrade acknowledges that the latozinemab failure has been absorbed operationally through the 47% workforce reduction in October 2025, and that the ABC platform is now the primary value driver. The $6 BTIG target implies significant upside from current levels, contingent on the PROGRESS-AD interim futility analysis expected in H1 2026.

Analyst Takeaways

These three upgrades share a common thread: analysts are rewarding companies that have reduced uncertainty, not necessarily those posting the strongest numbers. Among the three upgrades, HIMS has the most immediate catalyst with the Novo Nordisk partnership announcement, though both upgrading firms describe the current risk/reward as balanced following the stock’s sharp move. Deutsche Bank’s Teladoc upgrade is framed around valuation and a longer-term turnaround timeline. Alector’s BTIG upgrade is contingent on the PROGRESS-AD interim futility analysis expected in H1 2026.

Key Risks to Watch

• HIMS regulatory exposure: Both analyst upgrades note that 2026 guidance assumes continued access to compounded semaglutide. If that access is curtailed before branded Wegovy distribution scales, revenue estimates could face pressure. The company also carries approximately $1B in convertible debt from a May 2025 offering.
• Teladoc’s BetterHelp drag: The mental health segment posted an 8% revenue decline in Q3 2025 and the company recorded a $12.6M goodwill impairment charge. The insurance acceptance rollout in BetterHelp is a credible growth lever, but execution timelines remain uncertain and the business continues to generate net losses.
• Alector’s binary pipeline risk: The PROGRESS-AD interim futility analysis in H1 2026 could result in program discontinuation. With annual cash burn of approximately $142.9M and a runway only through 2027, a negative interim read would significantly pressure the stock and limit strategic options.